Chanan-Khan AA - Search Results

1

Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma.

Chanan-Khan AA, Lonial S, Weber D, Borrello I, Foà R, Hellmann A, Dimopoulos M, Swern AS, Knight R. Chanan-Khan AA, et al. Int J Hematol. 2012 Aug;96(2):254-62. doi: 10.1007/s12185-012-1125-7. Epub 2012 Jul 3. Int J Hematol. 2012. PMID: 22752567 Free PMC article.

2

Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT.

Ahmad I, Islam T, Chanan-Khan A, Hahn T, Wentling D, Becker JL, McCarthy PL Jr, Alam AR. Ahmad I, et al. Bone Marrow Transplant. 2002 Apr;29(7):577-80. doi: 10.1038/sj.bmt.1703522. Bone Marrow Transplant. 2002. PMID: 11979306

3

Bcl-2 antisense therapy in multiple myeloma.

Chanan-Khan AA. Chanan-Khan AA. Oncology (Williston Park). 2004 Nov;18(13 Suppl 10):21-4. Oncology (Williston Park). 2004. PMID: 15651173 Free article. Review.

4

Supportive care in multiple myeloma.

Chanan-Khan A, Miller KC. Chanan-Khan A, et al. Clin Lymphoma Myeloma. 2006 Jul;7(1):42-50. doi: 10.3816/CLM.2006.n.038. Clin Lymphoma Myeloma. 2006. PMID: 16879769 Review.

5

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.

Chanan-Khan A, Miller KC, Musial L, Lawrence D, Padmanabhan S, Takeshita K, Porter CW, Goodrich DW, Bernstein ZP, Wallace P, Spaner D, Mohr A, Byrne C, Hernandez-Ilizaliturri F, Chrystal C, Starostik P, Czuczman MS. Chanan-Khan A, et al. J Clin Oncol. 2006 Dec 1;24(34):5343-9. doi: 10.1200/JCO.2005.05.0401. Epub 2006 Nov 6. J Clin Oncol. 2006. PMID: 17088571 Clinical Trial.

6

Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study.

Chanan-Khan AA, Kaufman JL, Mehta J, Richardson PG, Miller KC, Lonial S, Munshi NC, Schlossman R, Tariman J, Singhal S. Chanan-Khan AA, et al. Blood. 2007 Mar 15;109(6):2604-6. doi: 10.1182/blood-2006-09-046409. Epub 2006 Nov 30. Blood. 2007. PMID: 17138816 Free article.

7

Bortezomib in combination with pegylated liposomal doxorubicin for the treatment of multiple myeloma.

Manochakian R, Miller KC, Chanan-Khan AA. Manochakian R, et al. Clin Lymphoma Myeloma. 2007 Jan;7(4):266-71. doi: 10.3816/CLM.2007.n.001. Clin Lymphoma Myeloma. 2007. PMID: 17324333 Review.

8

Multiple myeloma. Clinical practice guidelines in oncology.

Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Comenzo RL, De Castro CM, Djulbegovic B, Farag S, Huff CA, Meredith R, Schriber J, Shrieve D, Singhal S, Smith MR, Stockerl-Goldstein K, Vose JM, Weber D, Yahalom J, Yunus F; National Comprehensive Cancer Network (NCCN). Anderson KC, et al. J Natl Compr Canc Netw. 2007 Feb;5(2):118-47. doi: 10.6004/jnccn.2007.0014. J Natl Compr Canc Netw. 2007. PMID: 17335683 No abstract available.

9

Pegylated liposomal doxorubicin and immunomodulatory drug combinations in multiple myeloma: rationale and clinical experience.

Chanan-Khan AA, Lee K. Chanan-Khan AA, et al. Clin Lymphoma Myeloma. 2007 Apr;7 Suppl 4:S163-9. doi: 10.3816/clm.2007.s.018. Clin Lymphoma Myeloma. 2007. PMID: 17562255 Review.

10

Clinical impact of bortezomib in frontline regimens for patients with multiple myeloma.

Manochakian R, Miller KC, Chanan-Khan AA. Manochakian R, et al. Oncologist. 2007 Aug;12(8):978-90. doi: 10.1634/theoncologist.12-8-978. Oncologist. 2007. PMID: 17766658 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

229 results

Search Page

Filters